The information contained on this page is provided by the respective companies noted. It does not necessarily reflect the Society’s viewpoint and may redirect the user to a third-party site. ASE has posted this content on ContrastZone as a convenient way to access multiple pieces of information in one place, in alignment with our Society’s goal to provide resources and education to enhance the access to and quality in cardiovascular ultrasound.
Bracco Diagnostics
March 2016: LUMASON is now FDA approved for use in ultrasonography of the liver
Bracco Diagnostics Inc., the U.S. subsidiary of Bracco Imaging S.p.A., one of the world’s leading companies in the diagnostic imaging business, announced today that LUMASON is now approved for use in ultrasonography of the liver for characterization of focal liver lesions in adult and pediatric patients.
Please read the press release and prescribing information for more information.
Lumason Formulary Kit: includes Lumason Product Monograph, Safety Data Sheet, FDA Approval Letter, and Prescribing Information
Lumason Brochure: overview of product
2019 LUMASON® Reimbursement Guide
November 2015: Lumason® approved for reimbursement by CMS
To learn more about how to code Bracco’s new ultrasound contrast agent, visit here and read the press release here.
GE Healthcare
GE ultrasound contrast agent Optison gets FDA OK for label change
Optison Dosing, Handling, & Administration Training Video (updated link coming soon)
Optison Case Study Video (it is highly suggested that Google Chrome is used with this link)
Quick Reference Guide for Using Optison (updated link coming soon)
Preparation and Administration Guidelines (updated link coming soon)
Lantheus Medical Imaging
DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable Suspension
Lantheus Medical Imaging, Inc.
DEFINITY® Prescribing Information
